LLY是一只受青睐的股息增长股；高增长率与低派息率使其具吸引力，尽管股息率不足1%。
逐段跳播
好，最后，这就把我们带到了名单上的第五笔也是最后一笔买入。为此，我们实际上要转向医疗保健板块，不过在这份名单上我们已经谈了很多科技。事实上，这家公司里也有很多科技。所以，变化不算很大，但我们来看这家公司，另一个大型股息增长标的，也就是制药巨头 Eli Lilly（交易代码 LLY），BlackRock 在上个季度又买入了 13 亿美元，使其总持股超过 800 亿美元。
Okay, finally, this now brings us to the fifth and final purchase on the list. For this, we're actually going to be heading towards the healthcare sector, but we've already talked a lot about technology on this list.
In fact, there is a lot of technology in this company as well. So, not a very big change , but let's move on to this company, another big dividend growth option , namely pharmaceutical giant Eli Lilly ( trading symbol LLY), of which BlackRock acquired another $1.3 billion in the last quarter, bringing their total stake to more than $80 billion.
现在，和其他公司一样，这也是一只表现优异的股票，股价不断刷新纪录，但遗憾的是，按当前股价计算，其股息率不到 1%。但 Lily 在收入方面欠缺的地方，它在其他各个方面都以巨大的增长弥补了回来。
首先，它的股息增长率和增长历史都达到两位数，最重要的是，它的股息支付率非常低，只有约 20%，这对这样一家制药巨头来说至关重要，而且坦率地说也很罕见；因为这不仅使它们能够继续以高速度提高派息，还让它们拥有巨额现金流，可以投入到对制药和生物技术公司非常重要的领域，比如临床试验、工厂扩建和战略收购，而这正是 Lilly 近年来以近乎完美的技巧一直在做的事情。
Now, just like the others, this is another high-performing stock when it comes to a consistently record-breaking share price, unfortunately resulting in a dividend yield of less than 1% based on today's current share price.
But where Lily lacks revenue, it certainly makes up for it with tremendous growth in every other aspect. To begin with, both their dividend growth rate and growth history are in the double digits , and most importantly, their dividend payout ratio is very small, at only about 20%, which is vital and frankly rare for a pharmaceutical giant like this; Because this not only enables them to continue raising distributions at high rates, but also leaves them with huge cash flow that they can inject into things that are very important to pharmaceutical and biotechnology companies, such as clinical trials, factory expansions and strategic acquisitions, which is exactly what Lilly has been doing with near-perfect skill in recent years.
我们稍后会谈到这一点，但让我最后再展示一次百分比计算器。这次是针对 Lilly。如果你在 10 年前买入这只股票，它的成本大约是每股 67 美元。当你计算用 67 美元可以获得的当前每股股息时，你会发现你大约获得每股 7 美元的股息。这意味着超过 10% 的回报。
We will get to that in a little while, but let me show you the percentage calculator one last time . This time it's for Lilly. If you had bought the stock 10 years ago, it would have cost around $67 per share .
When you calculate the current dividend per share that you could have received for $67, you would find that you receive approximately $7 in dividends per share. This translates to a return of over 10%.
你能想象今天持有 Eli Lilly 的股票吗？它是制药板块最大的增长怪兽之一，不是吗？制药板块的每一位投资者都想持有 Lilly 的股票，因为它正在实现巨大的增长。你能想象它还支付超过 10% 的股息吗？
Can you imagine owning Eli Lilly shares today? It's one of the biggest growth monsters in the pharmaceutical sector , isn't it? Every investor in the pharmaceutical sector wants to own Lilly shares because of the tremendous growth it is achieving.
Can you imagine that it also pays dividends of more than 10%?
通常，要获得这样的股息率，你必须转向像 Pfizer 这样陷入困境的公司，那种股价已从疫情高峰期水平下跌的公司。一只遭受了这类损伤、股价大幅崩跌的股票。通常，要在制药板块获得高股息率，你需要这类股票。
你肯定不会想到像 Eli Lilly 这样的公司会出现这种情况。
Typically, to get that, you have to turn to a struggling company like Pfizer, something whose price has dropped from its peak pandemic levels, you know. A stock that has suffered damage of this type, where the stock price has collapsed significantly.
Typically, to get a high dividend yield in the pharmaceutical sector , you need this type of stock. You certainly wouldn't have expected to see that from a company like Eli Lilly.
但话说回来，这就是投资股息增长的力量。你只需要尽早入场并长期投资。你知道，很多人不应该发怒。但很多人批评长期投资，说：“哦，这全是短线交易的事。”他们低估了长期投资的重要性。这就是长期投资的力量。
你能想象 Eli Lilly 的股价表现如此强劲吗？按市值计算，它现在实际上是最大的制药巨头，因为股价涨得如此剧烈。不过，你也可以从中获得巨大的股息率。但话说回来，你需要成为长期投资者才能实现这一点。应该是这样。这是唯一的办法。
But again, this is the power of investing in dividend growth . You just need to get in early and invest for the long term. You know, many people shouldn't get into a rage. But many people criticize long-term investing and say, "Oh , it's all about short-term trading."
They underestimate the importance of long-term investment. This is the power of long-term investment. Can you imagine that Eli Lilly's stock performance was so strong? It is literally the largest pharmaceutical giant right now in terms of market capitalization because the share price has risen so dramatically.
However, you can also get a huge dividend yield from it as well. But again, you need to be a long-term investor to make that happen . It should be. It's the only way.
话虽如此，Eli Lilly 几乎完美地执行了你会期望制药巨头采取的那些策略。它们用于减肥和糖尿病的热门注射剂 Zipbound 和 Mongaroo 已成为它们的巨大收入来源，仅在上个季度就创造了数十亿美元的销售额，增长率分别为 46% 和 91%。
它们共同帮助 Lilly 占据了整个市场 60% 以上的份额。它们还在通过显示出非常强劲结果的新产品发布来扩张。它们进行了多项新收购，其中一些在其运营中得到了人工智能技术的支持。
它们宣布了人工智能领域的合作，甚至完成了新超级计算机“LilyPod”的建造，这台计算机现在被认为是世界上最强大的生物技术超级计算机。它由来自 Nvidia 的一千多块下一代“Blackwell”图形处理器提供算力。
这将极大地增强它们的研发管线、药物发现平台以及诸如此类的东西。所以未来也有很多值得期待的地方。由于这一切，分析师预计它们在收入和利润方面将继续实现巨大增长，而且由于规模庞大，它们已经是行业领导者。
Well, that being said , Eli Lilly executes those strategies you'd typically expect from pharmaceutical giants almost perfectly. Their popular injections, Zipbound and Mongaroo for weight loss and diabetes, have become a huge source of income for them, generating billions of dollars in sales with growth of 46% and 91% respectively in the last quarter alone.
Together, they helped Lilly capture more than 60% of this entire market. They are also expanding with new releases that are showing very strong results. They have made several new acquisitions, some of which are supported by artificial intelligence technologies in their operations.
They have announced partnerships in the field of artificial intelligence, and have even completed the construction of their new supercomputer, " LilyPod," which is now considered the most powerful biotechnology supercomputer in the world.
It is powered by more than a thousand next-generation " Blackwell" graphics processing units from Nvidia. This will greatly enhance their development pipeline, their drug discovery platform, and all that sort of thing.
So there is a lot to look forward to in the future as well. Because of all this, analysts expect tremendous growth to continue for them in terms of revenues and profits, and they are already leaders in the industry due to their huge size.
我的意思是，如果你想谈论增长，Lilly 符合所有标准，完全符合股息增长型投资者在这一类别中寻找的东西。甚至该股的估值也受益于所有这些增长，因为它把市盈率相对盈利增长比率（PEG）推低到了甚至低于板块的水平，如果你能相信的话。
也就是说，由于 PEG 比率中计入了巨大的增长，生物技术和制药板块中最令人向往的股票实际上相对于板块被低估了。
I mean, if you want to talk about growth, Lilly meets all the criteria and fits perfectly with what a distribution growth investor is looking for in this category. Even the stock's valuation benefits from all this growth, because it has pushed the price-to-earnings-to- growth (PEG) ratio to levels even lower than the sector, if you can believe it.
That is, the most desirable stock in the biotechnology and pharmaceuticals sector is actually undervalued by the sector due to the massive growth that is accounted for in the (PEG) ratio.
现在，我非常喜欢 Lily，会把它排在 KLA 之前，但我无法把它排到 Nvidia、Microsoft 或 Broadcom 这类公司同一水平上，我对这些公司更信任一些，它们也在我的投资组合中。
Now, I like Lily a lot and would give it preference over KLA, but I can't rank it on the same level as companies like Nvidia, Microsoft, or Broadcom, which I trust a little more and which are in my portfolio.
这个频道对 $LLY 的历次判断
Ale's World of Stocks 在这只股票上共 3 条判断，这里只列相邻的几条。